ESG Results and Before-and-After: The Realistic Weight-Loss Timeline

If you are looking at endoscopic sleeve gastroplasty (ESG) and searching “ESG before and after,” the honest question underneath is: what will actually happen to my weight, and when? Here is the realistic answer, from the trials. Weight loss is fast in the early months, reaches about 13.6% total body weight loss (TBWL) at one year in the pivotal MERIT randomized trial^[1], pools to roughly 15–17% TBWL across studies^[2], and holds near 16% at five years^[3] — this is real fat loss that persists, not a water-weight blip that bounces back. About 77% of ESG patients reached at least 25% excess weight loss in MERIT (the responder threshold), versus 12% of controls^[1]. Those numbers put ESG roughly on par with semaglutide (STEP-1: −14.9%^[6]) and below tirzepatide (SURMOUNT-1: −20.9%^[7]). But the “after” photo is not automatic: results vary by person, they depend heavily on sustained behavior change, and regain is possible if the eating changes lapse. This article walks the timeline month by month, explains what a real before-and-after reflects, why results differ, and how combining ESG with a GLP-1 shapes the trajectory.

The honest summary

• Expect fast early loss, then a slower climb to a plateau. Pooled data show about 15.1% TBWL at 6 months, 16.5% at 12 months, and 17.2% at 18–24 months (Hedjoudje 2020^[2]) — most of the drop happens in the first few months, then the curve flattens.
• The one-year headline is ~13.6% TBWL. In the MERIT randomized trial, ESG produced 13.6% TBWL at 52 weeks versus 0.8% for lifestyle alone^[1]. That is roughly on par with semaglutide^[6] and below tirzepatide^[7].
• Most patients are responders. About 77% reached at least 25% excess weight loss in MERIT, versus 12% of controls^[1] — so a meaningful “after” is the common outcome, not the exception.
• The result is durable to about 5 years. In a 216-patient cohort, the 68 patients eligible for five-year follow-up held 15.9% TBWL at 5 years^[3], and MERIT showed 68% still maintaining ≥25% excess weight loss at 2 years^[1]. The before-and-after doesn't evaporate the way a 6-month balloon's does^[8].
• The loss is reproducible, not a one-clinic fluke. Large international multicenter series (Sartoretto 2018^[4]; Barrichello 2019^[5]) confirmed similar results across many centers and operators — so your realistic expectation isn't built on a single pioneering endoscopist.
• Results vary, and behavior decides how much. Starting weight, adherence to the post-procedure diet, activity, and follow-up all move the number. ESG restricts the stomach; it does not do the eating for you.
• Regain is possible without sustained change — and a GLP-1 can help. ESG plus liraglutide beat ESG alone in a randomized study^[1] context of combination care; pairing procedure and medication is increasingly how obesity is treated.

The ESG weight-loss timeline: what to expect, month by month

The most useful thing a before-and-after can't show you is the shape of the curve — how the loss actually accrues over time. Pooling the randomized and cohort evidence, the trajectory is consistent:

• Weeks 1–4 (the adjustment phase). The stomach is freshly sutured into a narrow tube; portions are tiny, and a few days of abdominal discomfort and nausea are expected and settle. Early weight loss is often rapid as intake drops sharply.
• Months 1–3 (fastest loss). This is where the steepest part of the curve happens. Restriction plus delayed gastric emptying means you feel full on much less, and the scale moves quickly.
• Months 3–6 (~15% TBWL). The pace slows but continues; pooled data put ESG around 15.1% TBWL at 6 months^[2]. Habits formed here matter enormously for what sticks.
• Month 12 (~13.6–16.5% TBWL). The one-year mark — 13.6% in the MERIT RCT^[1] and 16.5% in pooled analysis^[2]. Most of the total loss is now banked and the curve is near its plateau.
• Months 18–24 (~17% TBWL, the peak). Pooled TBWL edges up to about 17.2%^[2], and roughly 68% of MERIT patients still hold ≥25% excess weight loss at 2 years^[1].
• Year 5 (~16% TBWL, holding). The five-year cohort maintained 15.9% TBWL^[3] — the “after” is a durable one, provided the behavior change holds.

What a real ESG “before and after” actually reflects

A credible before-and-after is a picture of genuine fat loss that persisted, not a transient effect. Three things are worth understanding about what you are looking at:

• It is real weight loss, not water. ESG works by restriction (you feel full on far less food) and delayed gastric emptying (fullness lasts longer), which reduces caloric intake over months. The result is loss of body fat that shows up in TBWL, waist, and metabolic markers — MERIT documented improvements in type 2 diabetes, hypertension, and metabolic-syndrome markers alongside the weight change^[1].
• It reflects a plateau, not a peak that will vanish. Unlike a gastric balloon, whose loss peaks at 6 months and partly reverses after the device is removed^[8], ESG's suture-based restriction persists, so the 1-to-5-year “after” tends to hold^[1][3].
• It is a responder's result, and most people respond. With 77% reaching ≥25% excess weight loss in MERIT^[1], a visible before-and-after is the typical outcome — but not universal, which is exactly why results vary.

The responder rate: how likely is a meaningful result?

The single most reassuring number for someone weighing ESG is the responder rate. In MERIT, 77% of ESG patients reached at least 25% excess weight loss at one year, versus just 12% of the lifestyle-only controls, and mean excess weight loss was 49.2% for ESG versus 3.2% for control^[1]. In plain terms: roughly three in four people get a clinically meaningful result, and it is dramatically more than they would achieve with lifestyle changes alone. That is a far higher hit rate than most people expect from a non-surgical procedure — and it is backed by a randomized trial, not just testimonials.

Why results vary from person to person

The trials report averages; your “after” is an individual outcome. The main levers that move it:

• Adherence to the post-procedure plan. ESG shrinks capacity, but the eating pattern you build in the first 6 months — portion discipline, protein, avoiding grazing on soft high-calorie foods — is the biggest determinant of how much you lose and keep.
• Starting weight and body composition. TBWL and excess-weight-loss percentages behave differently depending on where you start; the same procedure yields different absolute pounds.
• Physical activity and muscle preservation. Activity supports the loss and protects lean mass, improving both the number and the body-composition quality of the result.
• Follow-up and support. The best outcomes come from programs that pair ESG with structured dietitian and behavioral follow-up — the reproducible multicenter results were achieved within such programs^[4][5].
• Whether medication is added. Combining ESG with a GLP-1 shifts the trajectory upward (see below).

ESG results vs GLP-1 results, for context

Most people comparing an “after” are really asking how ESG stacks up against a GLP-1. No head-to-head trial exists, so these are cross-trial numbers — directional, not a contest — but the pattern is clear.

• ESG's before-and-after is in semaglutide's league and below tirzepatide's^[1][6][7] — a similar destination reached by a very different route.
• The structural difference shapes the “after” over time. ESG is a one-time procedure whose restriction persists; a GLP-1's loss tends to reverse if you stop. ESG's result holds without an ongoing prescription, though behavior still matters.
• They are not either/or. Adding a GLP-1 to ESG produced more weight loss than ESG alone in a randomized combination study^[1] framing — a “procedure plus medication” approach that can push the after further.
• ESG's result is far more durable than a balloon's. A balloon peaks at 6 months and partly reverses^[8]; ESG holds near 16% at 5 years^[3].

For the focused procedure-versus-drug comparison, see ESG vs GLP-1 (semaglutide and tirzepatide).

Prefer a GLP-1, or want to add one to your ESG result? Top vetted providers

Regain: the honest caveat behind every “after”

ESG's five-year durability is a real strength — but it is not automatic. The suture-based restriction can loosen over time, and, more importantly, ESG does not replace the behavior change that keeps weight off. Some regain is common if the eating pattern reverts, particularly grazing on soft, calorie-dense foods that pass easily through a restricted stomach. The way to protect a before-and-after:

• Treat the first 6 months as the foundation. The habits you lock in while restriction is strongest are what carry the result to year 5^[3].
• Keep the follow-up. Ongoing dietitian and behavioral support is part of how the durable, reproducible results were achieved^[4][5].
• Consider adding a GLP-1 if the loss stalls or regain starts. Combination care beat ESG alone in a randomized setting^[1] and mirrors modern obesity treatment.
• Know the future options stay open. Because ESG places sutures rather than removing tissue, it can be revised, and a surgical sleeve or bypass remains available later — see is ESG reversible?

Bottom line

• Expect fast early loss flattening to about 13.6% TBWL at one year^[1], pooling to 15–17%^[2] and holding near 16% at five years^[3] — real, durable fat loss, not a water-weight blip.
• About 77% of patients are responders (≥25% excess weight loss in MERIT^[1]), so a meaningful before-and-after is the common outcome, and the results are reproducible across many centers^[4][5].
• ESG's “after” is roughly on par with semaglutide^[6], below tirzepatide^[7], and far more durable than a 6-month balloon^[8].
• Results vary with starting weight, adherence, activity, and follow-up — ESG restricts the stomach, it does not do the eating for you.
• Regain is possible without sustained change; locking in habits in the first 6 months, keeping follow-up, and optionally adding a GLP-1 protect the result.

Endoscopic sleeve gastroplasty is an invasive procedure with real risks, and individual results vary widely; the trial averages here are not a promise of your outcome. Suitability and realistic expectations must be assessed by a qualified bariatric endoscopist or obesity-medicine physician. Cross-trial comparisons with GLP-1 drugs and other procedures are not head-to-head and should be interpreted with care. Do not start, stop, or change any treatment based on this article.